key: cord-1006209-sld4so75
authors: Zhou, J; Choi, S; Liu, H; Zhang, J; Tian, Y; Edlow, A G; Ezashi, T; Roberts, R M; Ma, W; Schust, D J
title: Is SARS-CoV-2 infection a risk factor for early pregnancy loss? ACE2 and TMPRSS2 co-expression and persistent replicative infection in primitive trophoblast
date: 2021-07-22
journal: J Infect Dis
DOI: 10.1093/infdis/jiab309
sha: 16cec2a7feb3036adcfd0c2305834a8bef9800d8
doc_id: 1006209
cord_uid: sld4so75

BACKGROUND: SARS-CoV-2 infection in term placenta is relatively rare. However, growing evidence suggests that susceptibility of the human placenta to infection may vary by gestational age and pathogen. For several viral infections, susceptibility appears to be greatest during early gestation. Infections of the peri-implantation placenta that result in pre-clinical pregnancy loss would typically go undetected. Little is known about the effects of SARS-CoV-2 on the peri-implantation human placenta since this time in pregnancy can only be modeled in vitro. METHODS: We used a human embryonic stem cell-derived model of peri-implantation placental development to assess patterns of ACE2 and TMPRSS2 transcription and protein expression in primitive trophoblast. These molecules are involved in SARS-CoV-2 cell entry and infection. We then infected the same trophoblast cell model with a clinical isolate of SARS-CoV-2, and documented infection dynamics. RESULTS: ACE2 and TMPRSS2 were transcribed and translated in stem-cell derived trophoblast, with preferential expression in syncytialized cells. These same syncytialized cells supported replicative and persistent infection by SARS-CoV-2, while non-syncytialized trophoblast cells in the same cultures did not. CONCLUSIONS: Co-expression of ACE2 and TMPRSS2 in early human embryonic stem cell-derived trophoblast and the robust and replicative infection limited to syncytiotrophoblast equivalents support the hypothesis that increased viral susceptibility may be a defining characteristic of primitive trophoblast. Potential implications of these findings for early pregnancy loss deserve further investigation.

While SARS-CoV-2 infection in pregnancy is known to be associated with severe maternal morbidity and mortality [1] [2] [3] [4] , fetal risk remains less well-delineated.

Studies have demonstrated an increased risk of preterm birth [4, 5] and stillbirth [6] [7] [8] associated with maternal SARS-CoV-2 infection, but evidence of other adverse pregnancy outcomes is less robust. Similarly, vertical (in utero) transmission of SARS-CoV-2 appears to be rare [9] [10] [11] [12] [13] [14] [15] , when studied in the setting of maternal infection at or near delivery. Perhaps this is due, in part, to rare maternal viremia and patterns of ACE2 and TMPRSS2 expression in term placenta which likely protect against placental infection [12] . Despite the relative rarity of placental infection in SARS-CoV-2 compared to other viral illnesses such as cytomegalovirus (CMV) [16, 17] and Zika virus (ZIKV) [18] , there is evidence that trophoblast can be infected with SARS-CoV-2 [10, 12, [19] [20] [21] .

Risk of placental infection in the peri-implantation period is unique because the anatomy of the placenta [22] and the immunology at the maternal-fetal interface [22, 23] differ dramatically from that of term placenta, and because pre-and periclinical losses make up the vast majority of all early pregnancy losses [24] . More specifically, for only the first two weeks after blastocyst implantation in humans, the leading edge of the placenta is comprised of a unique placental cell layer, the primitive trophoblast, that secretes pregnancy hormones and is invasive [22] . The tree-like, fetally-derived villi that are bathed in maternal blood and characterize the maternal-fetal interface of the mature placenta begin to develop thereafter. Unlike the immune environment at the maternal-fetal interface for the vast majority of the remainder of pregnancy, that during the this pre-villous stage of the human placentation is highly proinflammatory [23] , which may have implications for primitive A c c e p t e d M a n u s c r i p t trophoblast susceptibility to infection. While case-control [25] and cohort studies of women infected in the first trimester [26, 27] have reported that SARS-CoV-2 infection does not increase miscarriage rates, these studies report on pregnancies occurring after the switch from pre-villous to villous placentation. Moreover, reports of unchanged miscarriage rates in SARS-CoV-2 infection are in contrast to the increased prevalence of early pregnancy loss associated with maternal infection by the related coronaviruses, severe acute respiratory virus syndrome (SARS-CoV-1) and Middle East respiratory syndrome (MERS) [28, 29] . It is possible that the previllous placenta may be more easily infected by maternal SARS-CoV-2 than the placenta later in pregnancy [30, 31] and that the effects of such infections are currently undetected.

The potential for placental infection in early pregnancy remains regrettably understudied, due to difficulties inherent in evaluating pregnancy loss that may occur prior to clinically-recognized pregnancy. Very early placental infections that have devastating consequences could go undetected as preclinical pregnancy losses.

Alternatively, should infection occur after documentation of pregnancy and the pregnancy continues to term, early placental infections might no longer be detected at the time of delivery. There are concerning reports, however, that placental infection may be more severe in early pregnancy [21, [32] [33] [34] [35] . In addition, a series of studies at the RNA and protein levels have shown the major SARS-CoV-2 entry receptor, ACE2 [36] , and the post-binding processing protein, TMPRSS2 [36] , are transcribed and translated in the outer trophectoderm layer of the human blastocyst, which will become the placenta [37] [38] [39] . ACE2 and TMPRSS2 are also expressed in the villous placenta across all three trimesters of pregnancy [12, 19-21, 40, 41] , although these molecules are very rarely co-expressed in the same cell types, at A c c e p t e d M a n u s c r i p t least in term placenta [12, 42] , which would limit susceptibility of the term placenta to SARS-CoV-2 infection. The infectability of trophoblast cell subtypes and placental tissues from the earliest stages of pregnancy has been understudied [35, 38, 39] , because of ethical and logistical obstacles to obtaining normal tissues in early human pregnancy, and in maintaining these tissues to allow in vitro exposure to SARS-CoV-2.

In very early pregnancy, the pregnancy remains clinically undetectable and therefore cannot be studied by using primary cell isolates, nor can it be easily modeled in animals. Several laboratories, including our own, have developed models that mimic early human placental development. These include, among others, extended human blastocyst culture [43, 44] and the use of human embryonic stem cells, induced pluripotent stem cells [45] [46] [47] [48] , and trophoblast stem cells [49] . We have used human embryonic stem cells to create a model of primitive trophoblast: the transient, invasive, and syncytialized leading edge of the newly implanted blastocyst present only during the first two weeks of human pregnancy [45] [46] [47] . We previously demonstrated that these cells are highly susceptible to infection by different ZIKV strains, in contrast to trophoblasts isolated from term placentas [30, 31] . Using this model of the earliest events in post-implantation placental development, we assessed co-expression of ACE2 and TMPRSS2 and SARS-CoV-2 infection rates, viral replication and cytopathic effects in primitive and developing human placenta.

A c c e p t e d M a n u s c r i p t

All research was approved by Institutional Biosafety Committee and performed in the BSL-3 laboratory at the University of Missouri Laboratory for Infectious Disease Research (LIDR).

The stem cell-derived primitive trophoblast cell model was created as follows.

Human embryonic stem cells (ESC; H1, WA01, obtained from WiCell Research Institute, Madison, WI [50] ) were cultured in six-well tissue culture plates (Thermo Scientific) on Matrigel (BD Bioscience)-coated plates under an atmosphere of 5% (vol/vol) CO 2 /air at 37 °C in mTeSR1 medium (STEMCELL Technologies). The culture medium was changed daily, and the cells were passaged every 5-6 days.

The method for trophoblast differentiation has been described previously [46] and is briefly reviewed in the supplementary methods. Throughout the remainder of the manuscript, differentiated, human ESC-derived trophoblasts will be referred to as ESCd and/or BAP-treated cells, to reflect the ingredients of the media used to create ESCd (BMP4 (10 ng/mL), A83-01 (1 μM), and PD173074 (0.1 μM), or "BAP"). BAPtreated differentiated trophoblast cells were cultured for up to 8 days (Fig 1A) . A c c e p t e d M a n u s c r i p t

To determine the expression of ACE2 and TMPRSS2 in human embryonic stem cell (ESC)-derived trophoblasts, bulk RNAseq data from H1 ESC differentiated (ESCd) in vitro to primitive trophoblast by an 8-day exposure to BMP4 (10 ng/mL), A83-01 (1 μM), and PD173074 (0.1 μM), or "BAP" treatment was compared to that from H1 ESC maintained in culture media +FGF2 [undifferentiated control (ESCu)] ( Fig 1A) . c c e p t e d M a n u s c r i p t incubation time (Fig. 3) . Moreover, SARS-CoV-2 nucleocapsid (N) protein was detected in infected ESCd at all tested time points (Fig.4 and Fig. S1 ), further demonstrating that ESC-derived trophoblast supports both entry and replication of SARS-CoV-2. Noticeably, SARS-CoV-2 N protein was only detected in infected ESCu at the earliest time point (24 hpi) but not at later time points (48 and 96 hpi) ( Fig. 4 and Fig. S1 ). Interestingly, cytopathic effects (CPE) were not observed in BAP-differentiated trophoblast nor in undifferentiated ECS controls infected with SARS-CoV-2, in stark contrast to Vero 6 cells infected with SARS-CoV-2 (Fig. S1 ).

fetal outcomes have been inconsistent [12, 14, 25] . Data supporting the rarity of vertical transmission of SARS-CoV-2 after infection in late pregnancy are strong [12] , although the hypothesized reasons for this do not necessarily apply in early pregnancy, when receptor expression patterns and trophoblast response to infection can vary dramatically [9, 10, 12-15, 30, 31, 35, 42] . Whether SARS-CoV-2 infects early pregnancy tissue remains largely unknown, due to difficulties inherent in studying the earliest pregnancies, including miscarriages that might go clinically undetected. We were specifically interested in the effects of SARS-CoV-2 infection on early (pre-villous) pregnancy and early placental development, because while several papers have suggested that placental infection can occur in all trimesters of pregnancy [20, 21, 33] , infection risk may be higher in earlier stages of gestation [20, 21, 35] . Key anatomic and gene/protein expression differences between the early post-implantation pre-villous placenta and the full-term villous placenta may elucidate A c c e p t e d M a n u s c r i p t any increased early pregnancy susceptibility to SARS-CoV-2 infection [22, 30, 31, 35] .

The pre-villous placenta (from the time of implantation on or about day 7 postfertilization to the third week of pregnancy when it degenerates) is comprised of an inner layer of cytotrophoblast cells and an invasive, leading edge syncytiotrophoblast that interacts directly with the maternal decidua and its resident specialized immune cells, as well as with decidual glandular secretions and the maternal arteriolar and venous blood of the canalized structures that it invades [22, 23] . Pregnancy in humans at the immediate post-implantation stage is preclinical and can only be studied by in vitro modeling. In one such human model, extended blastocyst culture, co-expression of ACE2 and TMPRSS2, the proteins necessary for SARS-CoV-2 entry and infection [13] , was demonstrated in the trophectoderm and early trophoblast cells, including syncytiotrophoblast [44] .

The evolution of the mature villous structure begins at approximately three weeks post-fertilization. The mature placental villi will be comprised of a core containing fetal vessels that are separated from maternal blood by several layers of protection including maternally-derived stromal cells, proliferative cytotrophoblast cells, and a single, multinucleated, non-proliferative layer of syncytiotrophoblast.

Single cell RNAseq [52] , RNA in situ hybridization [12, 19] and immunohistochemical analyses [12, 19] of term placenta suggest that this villous structure helps to protect the fetus from vertical transmission of SARS-CoV-2 infection in pregnancy. While ACE2 and TMPRSS2 are expressed in the placenta, anatomic separation in the third trimester placenta makes transmission from mother to fetus through these proteins unlikely [12] . Further, while SARS-CoV-2 viremia occurs at the low rate of 10-27% of A c c e p t e d M a n u s c r i p t infected non-pregnant patients with severe/critical illness [53] [54] [55] , viremia may be exceedingly rare in pregnant women at term [12] .

Using a stem cell-derived model of early trophoblast development, we demonstrated co-expression of ACE2 and TMPRSS2 in vitro in modeled multinucleated syncytiotrophoblast. In vivo, these cells interact directly with the maternal decidua in the pre-villous placenta, and therefore may be susceptible to maternal infection. We demonstrated that viral infection with SARS-CoV-2 was followed by viral replication, but we did not detect cytopathic effects during the 96hour post-exposure culture period. Infection and virus production in this model was limited to the syncytialized areas that express both ACE2 and TMPRSS2. One other group demonstrated SARS-CoV-2 infection in tissues from very early, preimplantation stage, human pregnancy, although these findings have not yet undergone peer review [38] . In that study, human blastocyst trophectoderm biopsies were used for RNAseq analyses, and human blastocysts were used for immunohistochemistry to show transcription and protein co-expression of ACE2 and TMPRSS2. The authors then used SARS-CoV-2 spike protein-pseudotyped viruses to demonstrate viral entry in trophectoderm cells of discarded human blastocysts. Viral replication and cytopathic effects were not assessed.

Here, we report that in stem cell-derived trophoblast, ACE2 and TMPRSS2 transcripts and proteins were preferentially expressed or solely expressed in multinucleated, syncytialized cells and viral infection was similarly restricted. This pattern of viral infection mimics that seen in our ZIKV [30, 31] and Dengue virus In contrast to Vero cells, ESC-derived trophoblast cells did not exhibit SARS-CoV-2 related cytopathic effects over 96 hours, despite robust viral replication and maintenance in these cells. The reasons for a lack of lytic effects are unclear but may be specific to early placenta and deserve further investigation. We hypothesize that this phenomenon may be partly responsible for the rarity of vertical transmission A c c e p t e d M a n u s c r i p t of SARS-CoV-2 even in the presence of detectable placental infection. In addition, persistence of SARS-CoV-2 in the placenta could have effects far removed from the time of maternal infection. A report of a pregnant woman with known exposure and asymptomatic infection in the first trimester of pregnancy who suffered an early second trimester loss of a karyotypically normal fetus [21] is consistent with this possibility. At the time of this loss, the patient was negative for SARS-CoV-2 in the nasopharynx but had virus detectable by RT-PCR and immunohistochemistry in the placenta. Infection was found in both cytotrophoblast and syncytiotrophoblast of this placenta but was much more robust in the latter [21] .

In our experiments, control, undifferentiated ESC could be infected in vitro, despite the absence of ACE2 (Supplemental Fig 1; CM +FGF2 24h data) . On the other hand, infection levels were several log-fold lower than those in ESC-derived trophoblast that co-expressed ACE2 and TMPRSS2. There was no evidence of replication or persistence of the virus in control, undifferentiated ESCu cells. This suggests that SARS-CoV-2 is able to enter the undifferentiated control cells, likely through endocytosis, as demonstrated previously [30, 31, 56] . However, the lack of viral replication in undifferentiated ESC contrasts with reports from ACE2-negative human airway cells, where replication followed passive infection [56] . The underlying mechanisms allowing undifferentiated ESC to permit SARS-CoV-2 entry but preventing replication require further investigation.

Finally, detectable maternal viremia in SARS-CoV-2 infected pregnant women [12] is seldom reported. This raises the question of how the primitive trophoblast could become infected by SARS-CoV-2, an event we speculate might occur but typically go undetected. Possibly, the immunomodulatory milieu of placental hormones may protect from infection, with protection increasing with gestational age.

A c c e p t e d M a n u s c r i p t Many of the immunomodulatory pregnancy-related hormones found in high levels in maternal serum, and higher levels at the maternal-fetal interface at the end of pregnancy are present locally and systemically at the time of implantation, but at much lower levels. This may allow viremic events (and placental infection) in early gestation at levels resembling those in the non-pregnant population [53] [54] [55] . Levels of viremia in early pregnancy, particularly during preclinical pregnancy, have never been studied. The cells of the maternal endometrium in pregnancy (decidua) coexpress ACE2 and TMPRSS2 [57] , and SARS-CoV-2 can be detected in semen of infected men [58, 59] . Infection of decidual cells could allow for transmission from decidua to trophoblast at the time of implantation, and semen could mediate infection at the time of fertilization. ACE2 and TMPRSS2 co-expression has been demonstrated in single cell RNAseq analysis in human zygotes, and 2 and 4 cell embryos; after that ACE2 expression moves to the trophectoderm and primitive endoderm [37] demonstrating that early embryos are theoretically susceptible to infection by SARS-CoV-2. This outcome has been verified in extended human blastocyst cultures in vitro [44] and may have important implications for transmission during assisted reproduction, particularly via artificial insemination.

In summary, we hypothesize that the unique characteristics of the placenta and local maternal-fetal immune microenvironment during and soon after human blastocyst implantation may result in pre-clinical and early clinical pregnancy loss in maternal SARS-CoV-2 infection. The immune microenvironment at the maternal-fetal interface at the time of implantation is proinflammatory and differs from the protolerogenic environment otherwise characteristic of pregnancy [23] . This proinflammatory microenvironment may control viral infection locally and could exacerbate the intense inflammation seen in other SARS-CoV-2 infected tissues A c c e p t e d M a n u s c r i p t [60] , thereby promoting pregnancy loss. Our in vitro studies have shown that a model of peri-implantation placenta supports SARS-CoV-2 infection and replication. There are no reports on the effects of SARS-CoV-2 infection on very early pregnancy loss, even in early clinical pregnancy. These could be undertaken in assisted reproduction clinics, in which pregnancies are followed very closely with repeated and early testing. In light of known early pregnancy loss risk associated with other coronaviruses, including those that also use ACE2 for entry [28, 29] , and the M a n u s c r i p t

At day 4, ESCu and ESCd were infected with SARS-CoV-2 at an MOI of 0.5. The viral titers depicted are presented as means ± SDs (n=3). The asterisks (*) represent a statistically significant difference between groups (*p < 0.05; **p < 0.001, unpaired t test). 

The authors report no conflicts of interest.

This manuscript is new information that has not been published or presented previously. Data for Figure 1 was extracted from a publically available data set generated in our laboratories and referenced in the manuscript (Reference 47). The figure is new and this particular expression data has not been previously published.

A c c e p t e d M a n u s c r i p t

Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 -COVID-NET, 13 States

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Do three-dimensional modeling and printing technologies have an impact on the surgical success of percutaneous transsacral screw fixation?

Severe Coronavirus Infections in Pregnancy: A Systematic Review

Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy -SET-NET, 16 Jurisdictions

Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP SONPM registries

Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic

Effect of the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality outcomes in Nepal: a prospective observational study

Infant Outcomes Following Maternal Infection with SARS-CoV-2: First Report from the PRIORITY Study

Clinical Characteristics and Neonatal Outcomes of Pregnant Patients With COVID-19: A Systematic Review

Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load

A Possible Case of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Newborn With Positive Placental In Situ Hybridization of SARS-CoV-2 RNA

Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis

Analysis of SARS-CoV-2 vertical transmission during pregnancy

Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis

Histologic correlates of viral and bacterial infection of the placenta associated with severe morbidity and mortality in the newborn

Zika Virus Pathogenesis and Tissue Tropism

SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

SARS-CoV-2 infection of the placenta

Persistence of SARS-CoV-2 in the first trimester placenta leading to transplacental transmission and fetal demise from an asymptomatic mother

Implantation and the survival of early pregnancy

The unique immunological and microbial aspects of pregnancy

Frequency of implantation and early pregnancy loss in natural cycles

Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients

SARS-CoV-2 in first trimester pregnancy: a cohort study

COVID-19 pandemic effect on early pregnancy: are miscarriage rates altered, in asymptomatic women?

Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome

Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study

Vulnerability of primitive human placental trophoblast to Zika virus

African and Asian strains of Zika virus differ in their ability to infect and lyse primitive human placental trophoblast

COVID-19 infection in first trimester of pregnancy marked by a liver cytolysis in a woman previously treated by hydroxychloroquine for repeated implantation failure: a case report

Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection

SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface

SARS-CoV-2 ACE2 and TMPRSS2 Receptor Protein Expression Patterns Throughout Gestation

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Entry Factors: ACE2 and TMPRSS2 Are Expressed in

Human Pre-Implantation Embryos Are Permissive to SARS-CoV-2 Entry

HUMAN PRE-IMPLANTATION EMBRYOS ARE PERMISSIVE TO SARS-COV-2 ENTRY

Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta

A Single-Cell RNA Expression Map of Human Coronavirus Entry Factors

Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?

Single Cell Collection of Trophoblast Cells in Peri-implantation Stage Human Embryos

Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester

Early onset preeclampsia in a model for human placental trophoblast

Complete and unidirectional conversion of human embryonic stem cells to trophoblast by BMP4

Comparison of syncytiotrophoblast generated from human embryonic stem cells and from term placentas

Modeling preeclampsia using human induced pluripotent stem cells

Derivation of Human Trophoblast Stem Cells

Embryonic stem cell lines derived from human blastocysts

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12

Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?

Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2

Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell

The ACE2 expression of maternal-fetal interface and fetal organs indicates potential risk of vertical transmission of SARS-COV-2

Clinical characteristics and results of semen tests among men with coronavirus disease 2019

No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019

The first 12 months of COVID-19: a timeline of immunological insights

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t